Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Burn

Showing results (111-120 of 162) with videos related to

Pageof 17
Sort By:
Database : the Journal of Biological Databases and Curation|September 4, 2024
Global Globin Network and adopting genomic variant database requirements for thalassemiaHashim Halim-Fikri, Ninie Nadia Zulkipli, Hafiza Alauddin, et al.
Journal of Medical Genetics|October 21, 2024
Lynch syndrome diagnostic testing pathways in endometrial cancers: a nationwide English registry-based studyLucy Loong, Catherine Huntley, Joanna Pethick, et al.
American Journal of Human Genetics|March 27, 2003
Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 geneAnja Wagner, Alicia Barrows, Juul Th Wijnen, et al.
American Journal of Human Genetics|April 12, 2003
The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotypeHanne Meijers-Heijboer, Juul Wijnen, Hans Vasen, et al.
Plos One|March 25, 2009
Genetic variation in VEGF does not contribute significantly to the risk of congenital cardiovascular malformationHelen R Griffin, Darroch H Hall, Ana Topf, et al.
Cancer Prevention Research (Philadelphia, Pa.)|April 2, 2009
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib TrialMonica M Bertagnolli, Craig J Eagle, Ann G Zauber, et al.
BJS Open|September 5, 2023
Risk-stratified faecal immunochemical testing (FIT) for urgent colonoscopy in Lynch syndrome during the COVID-19 pandemicAnne G Lincoln, Sally C Benton, Carolyn Piggott, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 25, 2022
Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-upJohn C Mathers, Faye Elliott, Finlay Macrae, et al.
Plos One|February 10, 2018
Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populationsHarsh Sheth, Emma Northwood, Cornelia M Ulrich, et al.
Lancet (London, England)|June 15, 2020
Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trialJohn Burn, Harsh Sheth, Faye Elliott, et al.
Pageof 17

Showing results (111-120 of 162) with videos related to

Sort By:
Pageof 17
Database : the Journal of Biological Databases and Curation|September 4, 2024
Global Globin Network and adopting genomic variant database requirements for thalassemiaHashim Halim-Fikri, Ninie Nadia Zulkipli, Hafiza Alauddin, et al.
Journal of Medical Genetics|October 21, 2024
Lynch syndrome diagnostic testing pathways in endometrial cancers: a nationwide English registry-based studyLucy Loong, Catherine Huntley, Joanna Pethick, et al.
American Journal of Human Genetics|March 27, 2003
Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 geneAnja Wagner, Alicia Barrows, Juul Th Wijnen, et al.
American Journal of Human Genetics|April 12, 2003
The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotypeHanne Meijers-Heijboer, Juul Wijnen, Hans Vasen, et al.
Plos One|March 25, 2009
Genetic variation in VEGF does not contribute significantly to the risk of congenital cardiovascular malformationHelen R Griffin, Darroch H Hall, Ana Topf, et al.
Cancer Prevention Research (Philadelphia, Pa.)|April 2, 2009
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib TrialMonica M Bertagnolli, Craig J Eagle, Ann G Zauber, et al.
BJS Open|September 5, 2023
Risk-stratified faecal immunochemical testing (FIT) for urgent colonoscopy in Lynch syndrome during the COVID-19 pandemicAnne G Lincoln, Sally C Benton, Carolyn Piggott, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 25, 2022
Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-upJohn C Mathers, Faye Elliott, Finlay Macrae, et al.
Plos One|February 10, 2018
Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populationsHarsh Sheth, Emma Northwood, Cornelia M Ulrich, et al.
Lancet (London, England)|June 15, 2020
Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trialJohn Burn, Harsh Sheth, Faye Elliott, et al.
Pageof 17